サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1375993

血液スクリーニングの市場規模、シェア、動向分析レポート：技術別、製品別、地域別、セグメント予測、2023年～2030年

Blood Screening Market Size, Share & Trends Analysis Report By Technology (NAT, ELISA, CLIA & EIA, NGS, Western Blotting), By Product (Reagent, Instrument), By Region, And Segment Forecasts, 2023 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 90 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
血液スクリーニングの市場規模、シェア、動向分析レポート：技術別、製品別、地域別、セグメント予測、2023年～2030年
出版日: 2023年10月23日
発行: Grand View Research
ページ情報: 英文 90 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

血液スクリーニング市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の血液スクリーニング市場は、2023年から2030年にかけて11.7%のCAGRを記録し、2030年までに66億2,000万米ドルに達すると予測されています。

同市場の成長は、ドナーのスクリーニングの増加と市場参入企業による継続的な技術進歩に起因しています。血液スクリーニング検査の需要は、献血の増加、輸血感染症に対する意識の高まり、業界の技術開発により継続的に増加しています。さらに、さまざまな国の政府が、すべての献血血液をいくつかのウイルスについて検査することを義務付けています。

レシピエントが最も安全な血液製剤を受け取れるようにするためには、すべての献血血液に対して徹底的なスクリーニングが必要です。2015年現在、このような検査は、赤血球抗体と感染症病原体のスクリーニングで構成されている：HIV-1、HIV-2、肝炎ウイルス、ウエストナイルウイルス（WNV）、ヒトTリンパ向性ウイルス（HTLV）、T. Cruzi、T. pallidum（梅毒）。これらの検査結果がすべて陰性であることが献血の条件です。

技術開発により、検査の感度と効率は向上しています。例えば、2016年、米国FDAは、献血血液をスクリーニングするために、Hologic, Inc.とGrifolsのProcleixジカウイルスアッセイを承認しました。さらに、米国FDAは2013年に次世代シーケンス（NGS）技術を承認しました。この技術は従来のDNA分析法よりも安価で迅速です。

血液スクリーニング市場レポートハイライト

  • 試薬セグメントは、2022年に約73.0％の最大の収益シェアを占め、予測期間中に12.0％の最速CAGRで成長すると予測されます。
  • 北米は市場を独占し、2022年に39.0%の最大収益シェアを占めました。これは、主要な業界プレイヤーの存在、血液スクリーニングプロセスの採用の増加、輸血に関するFDAの厳しい規制、感染症流行の増加、患者の経済的負担の大きさなどが、予測期間中にその地位を維持する要因となっています。
  • アジア太平洋地域は、献血に対する意識の高まり、患者の経済的負担の増加、主要業界プレイヤーの新興国への注力により、予測期間中13.5％のCAGRで最も速い成長が見込まれています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 血液スクリーニング市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 普及と成長の見通しマッピング
  • 業界のバリューチェーン分析
    • 償還の枠組み
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 血液スクリーニング市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析

第4章 血液スクリーニング市場：技術の推定・動向分析

  • 血液スクリーニング市場：重要なポイント
  • 血液スクリーニング市場：動向と市場シェア分析、2022年および2030年
  • 核酸増幅（NAT）
  • ELISA
  • 化学発光免疫測定法（CLIA）および酵素免疫測定法（EIA）
  • 次世代シーケンス
  • ウェスタンブロッティング

第5章 血液スクリーニング市場：製品の推定・動向分析

  • 血液スクリーニング市場：重要なポイント
  • 血液スクリーニング市場：動向と市場シェア分析、2022年および2030年
  • 試薬
  • 機器

第6章 血液スクリーニング市場：地域の推定・動向分析

  • 地域別の展望
  • 地域別の血液スクリーニング市場：重要なポイント
  • 北米
    • 市場推計・予測、2018～2030年
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • スウェーデン
    • ノルウェー
    • デンマーク
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • オーストラリア
    • タイ
    • 韓国
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • サウジアラビア
    • 南アフリカ
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 市場参入企業の分類
    • Abbott
    • Danaher Corporation (Beckman Coulter)
    • Bio-Rad Laboratories, Inc.
    • Hoffman-La Roche Ltd.
    • Grifols, S.A.
    • Ortho-Clinical Diagnostics, Inc.
    • Siemens Healthcare GmbH
    • Thermo Fisher Scientific, Inc.
    • SOFINA s.a (Biomerieux)
図表

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America blood screening market, by technology, 2018 - 2030 (USD Million)
  • Table 3 North America blood screening market, by product, 2018 - 2030 (USD Million)
  • Table 4 North America blood screening market, by region, 2018 - 2030 (USD Million)
  • Table 5 U.S. blood screening market, by technology, 2018 - 2030 (USD Million)
  • Table 6 U.S. blood screening market, by product, 2018 - 2030 (USD Million)
  • Table 7 Canada blood screening market, by technology, 2018 - 2030 (USD Million)
  • Table 8 Canada blood screening market, by product, 2018 - 2030 (USD Million)
  • Table 9 Europe blood screening market, by technology, 2018 - 2030 (USD Million)
  • Table 10 Europe blood screening market, by product, 2018 - 2030 (USD Million)
  • Table 11 Europe blood screening market, by region, 2018 - 2030 (USD Million)
  • Table 12 Germany blood screening market, by technology, 2018 - 2030 (USD Million)
  • Table 13 Germany blood screening market, by product, 2018 - 2030 (USD Million)
  • Table 14 UK blood screening market, by technology, 2018 - 2030 (USD Million)
  • Table 15 UK blood screening market, by product, 2018 - 2030 (USD Million)
  • Table 16 France blood screening market, by technology, 2018 - 2030 (USD Million)
  • Table 17 France blood screening market, by product, 2018 - 2030 (USD Million)
  • Table 18 Italy blood screening market, by technology, 2018 - 2030 (USD Million)
  • Table 19 Italy blood screening market, by product, 2018 - 2030 (USD Million)
  • Table 20 Spain blood screening market, by technology, 2018 - 2030 (USD Million)
  • Table 21 Spain blood screening market, by product, 2018 - 2030 (USD Million)
  • Table 22 Sweden blood screening market, by technology, 2018 - 2030 (USD Million)
  • Table 23 Sweden blood screening market, by product, 2018 - 2030 (USD Million)
  • Table 24 Norway blood screening market, by technology, 2018 - 2030 (USD Million)
  • Table 25 Norway blood screening market, by product, 2018 - 2030 (USD Million)
  • Table 26 Denmark blood screening market, by technology, 2018 - 2030 (USD Million)
  • Table 27 Denmark blood screening market, by product, 2018 - 2030 (USD Million)
  • Table 28 Asia Pacific blood screening market, by technology, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific blood screening market, by product, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific blood screening market, by region, 2018 - 2030 (USD Million)
  • Table 31 Japan blood screening market, by technology, 2018 - 2030 (USD Million)
  • Table 32 Japan blood screening market, by product, 2018 - 2030 (USD Million)
  • Table 33 China blood screening market, by technology, 2018 - 2030 (USD Million)
  • Table 34 China blood screening market, by product, 2018 - 2030 (USD Million)
  • Table 35 India blood screening market, by technology, 2018 - 2030 (USD Million)
  • Table 36 India blood screening market, by product, 2018 - 2030 (USD Million)
  • Table 37 Australia blood screening market, by technology, 2018 - 2030 (USD Million)
  • Table 38 Australia blood screening market, by product, 2018 - 2030 (USD Million)
  • Table 39 Thailand blood screening market, by technology, 2018 - 2030 (USD Million)
  • Table 40 Thailand blood screening market, by product, 2018 - 2030 (USD Million)
  • Table 41 South Korea blood screening market, by technology, 2018 - 2030 (USD Million)
  • Table 42 South Korea blood screening market, by product, 2018 - 2030 (USD Million)
  • Table 43 Latin America blood screening market, by technology, 2018 - 2030 (USD Million)
  • Table 44 Latin America blood screening market, by product, 2018 - 2030 (USD Million)
  • Table 45 Latin America blood screening market, by region, 2018 - 2030 (USD Million)
  • Table 46 Brazil blood screening market, by technology, 2018 - 2030 (USD Million)
  • Table 47 Brazil blood screening market, by product, 2018 - 2030 (USD Million)
  • Table 48 Mexico blood screening market, by technology, 2018 - 2030 (USD Million)
  • Table 49 Mexico blood screening market, by product, 2018 - 2030 (USD Million)
  • Table 50 Argentina blood screening market, by technology, 2018 - 2030 (USD Million)
  • Table 51 Argentina blood screening market, by product, 2018 - 2030 (USD Million)
  • Table 52 Middle East and Africa blood screening market, by technology, 2018 - 2030 (USD Million)
  • Table 53 Middle East and Africa blood screening market, by product, 2018 - 2030 (USD Million)
  • Table 54 Middle East and Africa blood screening market, by region, 2018 - 2030 (USD Million)
  • Table 55 South Africa blood screening market, by technology, 2018 - 2030 (USD Million)
  • Table 56 South Africa blood screening market, by product, 2018 - 2030 (USD Million)
  • Table 57 Saudi Arabia blood screening market, by technology, 2018 - 2030 (USD Million)
  • Table 58 Saudi Arabia blood screening market, by product, 2018 - 2030 (USD Million)
  • Table 59 UAE blood screening market, by technology, 2018 - 2030 (USD Million)
  • Table 60 UAE blood screening market, by product, 2018 - 2030 (USD Million)
  • Table 61 Kuwait blood screening market, by technology, 2018 - 2030 (USD Million)
  • Table 62 Kuwait blood screening market, by product, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Blood screening: Market outlook
  • Fig. 9 Blood screening: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Blood screening market driver impact
  • Fig. 15 Blood screening market restraint impact
  • Fig. 16 Blood screening market strategic initiatives analysis
  • Fig. 17 Blood screening market: Technology movement analysis
  • Fig. 18 Blood screening market: Technology outlook and key takeaways
  • Fig. 19 Nucleic acid amplification (NAT) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 ELISA market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Chemiluminescence immunoassay (CLIA) and enzyme immunoassay (EIA) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Next generation sequencing (NGS) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Western blotting market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Blood screening market: Product movement analysis
  • Fig. 25 Blood screening market: Product outlook and key takeaways
  • Fig. 26 Reagent market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Instrument market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Global blood screening market: Regional movement analysis
  • Fig. 29 Global blood screening market: Regional outlook and key takeaways
  • Fig. 30 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Middle East and Africa. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
目次
Product Code: GVR-1-68038-215-0

Blood Screening Market Growth & Trends:

The global blood screening market is expected to reach USD 6.62 billion by 2030, registering a CAGR of 11.7% from 2023 to 2030, according to a new report by Grand View Research, Inc.. The growth of the market is attributed to the increase in screening of donor and continuous technological advancement by the market players. Demand for blood screening tests is increasing continuously due to increasing donation, rising awareness about transfusion-transmitted diseases, and technological developments in the industry. Furthermore, governments of various countries are in process to mandates testing all donated blood for several viruses.

Thorough screening is necessary for all donated blood to ensure that recipients receive the safest products. As of 2015, such testing consists of screening for red cell antibodies, and the infectious diseases agents: HIV-1, HIV-2, hepatitis virus, West Nile Virus (WNV), Human T-Lymphotropic Virus (HTLV) T. Cruzi, and T. pallidum (syphilis). The result of all these assays must be negative for blood donation.

Technological developments increase the sensitivity and efficiency of the tests. For instance, in 2016, the U.S. FDA approved the Procleix Zika virus assay from Hologic, Inc. and Grifols to screen donated blood. Furthermore, the U.S. FDA approved next-generation sequencing (NGS) technology in 2013. The technology is cheaper and faster than previous DNA analysis methods.

Blood Screening Market Report Highlights:

  • The reagent segment accounted for the largest revenue share of around 73.0% in 2022 and is expected to grow at the fastest CAGR of 12.0% over the forecast period.
  • North America dominated the market and accounted for the largest revenue share of 39.0% in 2022 owing to the presence of key industry players, increased adoption of the blood screening process, stringent FDA regulations for transfusion, rising infectious disease prevalence, and greater patient affordability are responsible for maintaining its position during the forecast period.
  • Asia Pacific is expected to grow at the fastest CAGR of 13.5% over the forecast period owing to increasing awareness about blood donation, rising patient affordability, and the focus of key industry players on emerging countries in the region.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Technology
    • 1.1.2. Product
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Technology outlook
    • 2.2.2. Product outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Blood Screening Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Industry Value Chain Analysis
    • 3.3.1. Reimbursement framework
  • 3.4. Market Dynamics
    • 3.4.1. Market driver analysis
    • 3.4.2. Market restraint analysis
  • 3.5. Blood Screening Market Analysis Tools
    • 3.5.1. Industry Analysis - Porter's
      • 3.5.1.1. Supplier power
      • 3.5.1.2. Buyer power
      • 3.5.1.3. Substitution threat
      • 3.5.1.4. Threat of new entrant
      • 3.5.1.5. Competitive rivalry
    • 3.5.2. PESTEL Analysis
      • 3.5.2.1. Political landscape
      • 3.5.2.2. Technological landscape
      • 3.5.2.3. Economic landscape

Chapter 4. Blood Screening Market: Technology Estimates & Trend Analysis

  • 4.1. Blood Screening Market: Key Takeaways
  • 4.2. Blood Screening Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Nucleic Acid Amplification (NAT)
    • 4.3.1. Nucleic acid amplification (NAT) market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. ELISA
    • 4.4.1. ELISA market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)
    • 4.5.1. Chemiluminescence immunoassay (CLIA) and enzyme immunoassay (EIA) market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.6. Next-Generation Sequencing
    • 4.6.1. Next-generation sequencing market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.7. Western Blotting
    • 4.7.1. Western blotting market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Blood Screening Market: Product Estimates & Trend Analysis

  • 5.1. Blood Screening Market: Key Takeaways
  • 5.2. Blood Screening Market: Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Reagent
    • 5.3.1. Reagent market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4. Instrument
    • 5.4.1. Instrument market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Blood Screening Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Outlook
  • 6.2. Blood Screening Market by Region: Key Takeaway
  • 6.3. North America
    • 6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.2. U.S.
      • 6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.3. Canada
      • 6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.3. France
      • 6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.6. Sweden
      • 6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.7. Norway
      • 6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.8. Denmark
      • 6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.2. China
      • 6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.3. India
      • 6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.5. Thailand
      • 6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.6. South Korea
      • 6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.2. Mexico
      • 6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.3. Argentina
      • 6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7. MEA
    • 6.7.1. Saudi Arabia
      • 6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.2. South Africa
      • 6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Market Participant Categorization
    • 7.2.1. Abbott
      • 7.2.1.1. Company overview
      • 7.2.1.2. Financial performance
      • 7.2.1.3. Product benchmarking
      • 7.2.1.4. Strategic initiatives
    • 7.2.2. Danaher Corporation (Beckman Coulter)
      • 7.2.2.1. Company overview
      • 7.2.2.2. Financial performance
      • 7.2.2.3. Product benchmarking
      • 7.2.2.4. Strategic initiatives
    • 7.2.3. Bio-Rad Laboratories, Inc.
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Product benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. Hoffman-La Roche Ltd.
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Product benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. Grifols, S.A.
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. Ortho-Clinical Diagnostics, Inc.
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Product benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. Siemens Healthcare GmbH
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Product benchmarking
      • 7.2.7.4. Strategic initiatives
    • 7.2.8. Thermo Fisher Scientific, Inc.
      • 7.2.8.1. Company overview
      • 7.2.8.2. Financial performance
      • 7.2.8.3. Product benchmarking
      • 7.2.8.4. Strategic initiatives
    • 7.2.9. SOFINA s.a (Biomerieux)
      • 7.2.9.1. Company overview
      • 7.2.9.2. Financial performance
      • 7.2.9.3. Product benchmarking
      • 7.2.9.4. Strategic initiatives